Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
36.9M
-
Shares change
-
+5.38M
-
Total reported value, excl. options
-
$1.92B
-
Value change
-
+$310M
-
Number of buys
-
82
-
Number of sells
-
-16
-
Price
-
$51.94
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q4 2020
107 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q4 2020.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.9M shares
of 72.2M outstanding shares and own 51.1% of the company stock.
Largest 10 shareholders include FMR LLC (6.09M shares), Matrix Capital Management Company, LP (3.82M shares), VIKING GLOBAL INVESTORS LP (3.01M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.66M shares), Redmile Group, LLC (2.42M shares), VANGUARD GROUP INC (2.35M shares), BlackRock Inc. (2.28M shares), CITADEL ADVISORS LLC (1.5M shares), PRIMECAP MANAGEMENT CO/CA/ (1.37M shares), and Avidity Partners Management LP (1.14M shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.